Agios executive awarded RSUs and stock options

AGIOS PHARMACEUTICALS, INC. executive Krishnan Viswanadhan, Chief Corporate Development & Strategy, reported equity compensation grants rather than market purchases or sales.

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. executive Krishnan Viswanadhan, Chief Corporate Development & Strategy, reported equity compensation grants rather than market purchases or sales. He received 14,000 restricted stock units, each representing a right to one share of common stock.

The restricted stock units were granted on March 1, 2026 and will vest in three equal annual installments beginning March 1, 2027. He was also granted stock options covering 52,000 shares at a per-share exercise price of $0.00, vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments thereafter.

Insider Trade Summary

Grant/Award: 66,000 shares

Grant/Award 2 txns

Insider Viswanadhan Krishnan

Role Chief Corp Dev & Strategy

Type	Security	Shares	Price	Value
Grant/Award	Restricted stock units	14,000	$0.00	$0.00
Grant/Award	Stock options (right to buy)	52,000	$0.00	$0.00

Holdings After Transaction: Restricted stock units — 14,000 contracts (Direct); Stock options (right to buy) — 52,000 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
2. F2. The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.
3. F3. This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AGIO executive Krishnan Viswanadhan report on this Form 4?

Krishnan Viswanadhan reported equity awards, not open-market trades. He received 14,000 restricted stock units and stock options for 52,000 shares, both granted on March 1, 2026 as part of his compensation package.

How many restricted stock units were granted to the AGIO executive and how do they vest?

He was granted 14,000 restricted stock units. These were granted on March 1, 2026 and will vest in three equal annual installments starting March 1, 2027, meaning one-third of the units becomes deliverable each year.

What are the terms of the 52,000 AGIO stock options granted to Krishnan Viswanadhan?

He received stock options covering 52,000 shares on March 1, 2026 at an exercise price of $0.00. Twenty-five percent vest on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments afterward.

Is the AGIO Form 4 filing a sign of insider buying or selling in the market?

The filing reflects equity compensation grants, not market buying or selling. The transactions are coded as awards (code A), representing restricted stock units and stock options granted to the executive, with vesting schedules extending from March 2027 onward.

Does Krishnan Viswanadhan hold these AGIO awards directly or through another entity?

The Form 4 indicates direct ownership for both awards. The restricted stock units and stock options are marked as directly owned, with no footnotes stating that another entity or person holds voting or investment authority over the reported securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Viswanadhan Krishnan

(Last) (First) (Middle)

88 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Corp Dev & Strategy

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted stock units	(1)	03/01/2026		A		14,000		(2)	(2)	Common stock	14,000	$0	14,000	D
Stock options (right to buy)	$30.23	03/01/2026		A		52,000		(3)	03/01/2036	Common stock	52,000	$0	52,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.

3. This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

	/s/ William Cook, as Attorney in Fact for Krishnan Viswanadhan	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.